Access cutting-edge esophageal neoplasms treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Houston location
Preparing your pre-screening questions…
Access esophageal neoplasms specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related esophageal neoplasms treatment provided free
Check if you qualify for this esophageal neoplasms clinical trial in Houston, TX
No-Cost Study Care
Local to Houston
Convenient for TX residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Background: Lymph node status is an important prognostic parameter in esophageal carcinoma and an independent predictor of survival. Distribution of metastatic lymph nodes may vary with tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy. Surgical strategy depends on the distribution pattern of nodal metastases but consensus on the extent of lymphadenectomy differs worldwide. Especially for adenocarcinoma the distribution of lymph node metastases has not yet been described in large series. Aim of the present study is to evaluate the distribution of lymph node metastases in esophageal carcinoma specimens following transthoracic esophagectomy with at least a 2-field lymphadenectomy. Methods: The TIGER-study is a multinational observational cohort study. All patients with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed in participating centers will be included. All lymph node stations will be excised and separately sent for pathological examination. Cluster analysis will be performed to identify patterns of metastases in relation to tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy. Conclusion: TIGER will provide a roadmap of the location of lymph node metastases in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and survival. Patient-tailored treatment can be developed on the basis of these results, such as the the optimal radiation field and extent of lymphadenectomy based on the primary tumor characteristics.
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Yes, this clinical trial (NCT03222895) has an active research site in Houston, TX that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for esophageal neoplasms treatment options in Houston, TX, this clinical trial (NCT03222895) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced esophageal neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all esophageal neoplasms clinical trials near you to find additional studies recruiting in your area.
See all multiple sclerosis clinical trials recruiting in Houston — not just this study.
Browse Multiple Sclerosis Trials in Houston →